TAG:
clinical trials
“Companion Diagnostics” Enter Lab Marketplace
By Robert Michel | From the Volume X No. 8 – June 16, 2003 Issue
CEO SUMMARY: Although the field of pharmacogenomics is still in its infancy, it has begun to develop sub-specialty areas. “Companion diagnostics” describes the marriage of a therapeutic drug with a specific diagnostic assay that can identify which patients will benefit from a prescrip…
New Market Channel For Esoteric Testing
By Robert Michel | From the Volume X No. 1 – January 20, 2003 Issue
CEO SUMMARY: It’s a new marketing model for specialty esoteric tests that presents both clinical and financial challenges to hospital and health system laboratories. Niche labs offering esoteric tests are sending sales reps directly to physicians and bypassing pathologists and lab direc…
Quiet Changes To Ripple Drugs-of-Abuse Market
By Robert Michel | From the Volume IX No. 17 – December 9, 2002 Issue
CEO SUMMARY: Drugs-of-abuse (DOA) testing is an intensely-competitive market poised for significant change. Historically, national lab companies have been the major players and used rock-bottom prices to control the nation’s biggest corporate DOA clients. But since this line of testing …
Esoterix Ready to Launch National Marketing Blitz
By Robert Michel | From the Volume IX No. 13 – September 16, 2002 Issue
CEO SUMMARY: It was 1995 when several specialty testing lab companies were acquired by a new company called Esoterix. Immediately the lab industry viewed Esoterix as a “put-together” lab company. However, since 2000, executives at Esoterix have invested $50 million to integrate operat…
AACC’s E-Lab Confab Emphasizes Lab Data
By Robert Michel | From the Volume IX No. 4 – March 11, 2002 Issue
CEO SUMMARY: In just six years, experts at the AACC’s E-Lab gathering predict that 50% of all diagnostic testing will be done as point-of-care, homecare, or kit testing. If true, this will be a swift transformation in how labs organize themselves to manage the diagnostic testing needs o…
IMPATH Buys Tamtron In Surprise Decision
By Robert Michel | From the Volume IX No. 2 – January 28, 2002 Issue
CEO SUMMARY: In an unexpected announcement, IMPATH, Inc. announced it would purchase Tamtron Corp., the largest remaining independent vendor of anatomic pathology systems. It was just months earlier that Cerner Corporation acquired Dynamic Healthcare Technologies, Inc. and its CoPath™ p…
Tripath Imaging Ready To Roil Pap Test Market
By Robert Michel | From the Volume VIII No. 17 – December 17, 2001 Issue
CEO SUMMARY: Single-handedly, Cytyc Corporation has built the market for thin-layer Pap smear testing. Executives at TriPath Imaging are now ready to challenge Cytyc’s dominance by offering what they believe is a different value proposition to labs: an automated liquid preparation syste…
New Lab Company Ready To Open In Orlando, FL
By Robert Michel | From the Volume VIII No. 17 – December 17, 2001 Issue
CEO SUMMARY: Within the next 60 days, a brand-new clinical laboratory company will begin operations in Orlando, Florida. In the short term, it plans to offer routine testing to physicians’ offices. However, the real goal is to create a laboratory organization with integrated information…
Beckman Coulter Positions Itself For Biotech Testing Continuum
By Robert Michel | From the Volume VIII No. 16 – November 26, 2001 Issue
CEO SUMMARY: Here’s a little-known side to diagnostics giant Beckman Coulter Inc. Its efforts to expand into the fields of biomedical R&D and clinical research is a strategic shift designed to give it early access to promising technology that could be introduced into the clinical di…
8 “Must Have” Features For Web Lab Test Reports
CEO SUMMARY: A growing number of laboratories have implemented Web-accessed lab test reporting for their office-based physician clients. Having participated in the design, sale and installation of many of these systems, Cory Fishkin gained valuable insights into the “do’s & don’…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized